Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
AssigneeTheravance Biopharma R&D IP, LLC
InventorsRyan Hudson, Jennifer Kozak, Dante D. Podesto, Xiaojun Huang, Venkat R. Thalladi
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for treating ulcerative colitis using a compound of the formula: or a pharmaceutically-acceptable salt thereof.
Claims56
A method for treating ulcerative colitis in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A method for treating ulcerative colitis in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of the formula:
A method for treating ulcerative colitis in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a crystalline form of a compound of the formula:
- wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at degrees 2θ values of 7.87°±0.20°, 12.78°±0.20°, 15.78°±0.20°, and 20.41°±0.20°.
A method for treating ulcerative colitis in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A method for treating ulcerative colitis in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:
A method for treating ulcerative colitis in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a crystalline form of a compound of the formula:
- wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at degrees 2θ values of 7.87°±0.20°, 12.78°±0.20°, 15.78°±0.20°, and 20.41°±0.20°.
A method for treating ulcerative colitis in a human, the method comprising administering orally to the human a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A method for treating ulcerative colitis in a human, the method comprising administering orally to the human a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:
A method for treating ulcerative colitis in a human, the method comprising administering orally to the human a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a crystalline form of a compound of the formula:
- wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at degrees 2θ values of 7.87°±0.20°, 12.78°±0.20°, 15.78°±0.20°, and 20.41°±0.20°.
Dependencies are inferred from the claim text.